Real-World Data on the Effects of Cardiac Resynchronization Therapy in Adult Patients With Congenital Heart Disease
Launched by LEIDEN UNIVERSITY MEDICAL CENTER · May 13, 2025
Trial Information
Current as of June 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a treatment called cardiac resynchronization therapy (CRT) in adults with congenital heart disease (ACHD). The goal is to find out if CRT can help improve health outcomes for these patients and to understand which patients might benefit the most from this therapy. This research is important because adults with congenital heart disease often have unique health challenges.
To participate in the trial, you need to be an adult who has already received CRT. If you're 18 years old or older and have undergone this treatment, you might be eligible to join. The trial is currently looking for participants, and if you decide to take part, you can expect to share your experiences and health data related to the therapy. This study aims to gather real-world information to help improve care for others with similar conditions in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ACHD patients who underwent CRT implantation
- Exclusion Criteria:
- • Less than 18 years old on the moment of CRT implantation
- • Patient objection to the use of retrospective data
About Leiden University Medical Center
Leiden University Medical Center (LUMC) is a prominent academic medical center located in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and high-quality patient care. As a clinical trial sponsor, LUMC focuses on translating scientific discoveries into effective therapies, fostering collaborations between researchers, clinicians, and industry partners. The center is dedicated to conducting rigorous clinical studies across various medical fields, ensuring adherence to ethical standards and regulatory requirements while prioritizing patient safety and outcomes. Through its multidisciplinary approach, LUMC aims to contribute significantly to the understanding and treatment of complex health conditions, driving progress in personalized medicine and improving global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leiden, Zuid Holland, Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported